-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, FVLD61mewimywUUZ4P5JzVlz68n0ZhYQCztriryCzgEKNolNKzYDZfKDdaL6v5Df XfI/X3Lvnu/Uboabi9qcJA== /in/edgar/work/20000609/0000893220-00-000754/0000893220-00-000754.txt : 20000919 0000893220-00-000754.hdr.sgml : 20000919 ACCESSION NUMBER: 0000893220-00-000754 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20000609 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: KOS PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001018952 STANDARD INDUSTRIAL CLASSIFICATION: [2834 ] IRS NUMBER: 650670898 STATE OF INCORPORATION: FL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: SEC FILE NUMBER: 005-52857 FILM NUMBER: 651906 BUSINESS ADDRESS: STREET 1: 1001 BRICKELL BAY DR STE 25 CITY: MIAMI STATE: FL ZIP: 33131 BUSINESS PHONE: 3055773464 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: DUPONT E I DE NEMOURS & CO CENTRAL INDEX KEY: 0000030554 STANDARD INDUSTRIAL CLASSIFICATION: [2820 ] IRS NUMBER: 510014090 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: 1007 MARKET ST CITY: WILMINGTON STATE: DE ZIP: 19898 BUSINESS PHONE: 3027741000 SC 13G 1 0001.txt SCHEDULE 13G 1 Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 KOS PHARMACEUTICALS, INC. (Name of Issuer) COMMON STOCK, $0.01 PAR VALUE (Title of Class of Securities) 500648 10 0 (CUSIP Number) MAY 31, 2000 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ ] 13d-1(b) [X] 13d-1(c) [ ] 13d-1(d) The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that Section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). 2 CUSIP NUMBER: 500648 10 0 PAGE 2 OF 6 PAGES - ------------------------------------------------------------------------------- 1) Names of Reporting Persons; I.R.S. Identification Nos. (entities only) E. I. DuPont de Nemours and Company - ------------------------------------------------------------------------------- 2) Check the Appropriate Box if a Member of a Group (See Instructions) (a) ____ (b) ____ - ------------------------------------------------------------------------------- 3) SEC Use Only - ------------------------------------------------------------------------------- 4) Citizenship or Place of Organization Delaware - ------------------------------------------------------------------------------- Number of 5) Sole Voting Power 1,250,000 Shares ------------------------------------------------------- Beneficially Owned by 6) Shared Voting Power 0 Each Reporting ------------------------------------------------------- Person With 7) Sole Dispositive Power 1,250,000 ------------------------------------------------------- 8) Shared Dispositive Power 0 - ------------------------------------------------------------------------------- 9) Aggregate Amount Beneficially Owned by Each Reporting Person 1,250,000 - ------------------------------------------------------------------------------- 10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] - ------------------------------------------------------------------------------- 11) Percent of Class Represented by Amount in Row (9) 6.4 % - ------------------------------------------------------------------------------- 12) Type of Reporting Persons (See Instructions) CO - ------------------------------------------------------------------------------- 3 CUSIP NUMBER: 500648 10 0 PAGE 3 OF 6 PAGES ITEM 1. (a) Name of issuer: Kos Pharmaceuticals, Inc. (b) Address of issuer's principal executive offices: 1001 Brickell Bay Drive 25th Floor Miami, Florida 33131 ITEM 2. (a) Name of person filing: E.I. du Pont de Nemours and Company (b) Address of principal business office or, if none, residence: 1007 Market Street Wilmington, Delaware 19898 (c) Citizenship: Delaware (d) Title of class of securities: Common Stock, $0.01 Par Value (e) CUSIP Number: 500648 10 0 4 CUSIP NUMBER: 500648 10 0 PAGE 4 OF 6 PAGES ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO RULE 13D-1(b), OR 13D-2(b), CHECK WHETHER THE PERSON FILING IS A: Not applicable ITEM 4. OWNERSHIP. (a) Amount beneficially owned: 1,250,000 (b) Percent of class: 6.4 % (c) Number of shares as to which such person has: (i) Sole power to vote or to direct the vote: 1,250,000 (ii) Shared power to vote or to direct the vote: 0 (iii) Sole power to dispose or to direct the disposition of: 1,250,000 (iv) Shared power to dispose or to direct the disposition of: 0 ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS: Not applicable ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON: Not applicable ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY: See Exhibit 1 5 CUSIP NUMBER: 500648 10 0 PAGE 5 OF 6 PAGES ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP: Not applicable ITEM 9. NOTICE OF DISSOLUTION OF GROUP: Not applicable ITEM 10. CERTIFICATION: By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. 6 CUSIP NUMBER: 500648 10 0 PAGE 6 OF 6 PAGES SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement on Schedule 13G is true, complete and correct as of the date hereof. E.I. DU PONT DE NEMOURS AND COMPANY Dated: June 9, 2000 By: /s/ Susan M. Stalnecker --------------------------------- Name: Susan M. Stalnecker Title: Vice President and Treasurer Index to Exhibits: Exhibit 1 - Identification and Classification of the Subsidiary. EX-1 2 0002.txt IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDARY 1 EXHIBIT 1 DuPont Pharmaceuticals Company, a Delaware general partnership and a wholly-owned subsidiary of E.I. du Pont de Nemours and Company, acquired the securities being reported on by E.I. du Pont de Nemours and Company in this Schedule 13G. E.I. du Pont de Nemours and Company and DuPont Pharma, Inc., a Delaware corporation, are the sole partners of DuPont Pharmaceuticals Company. DuPont Chemical and Energy Operations, Inc. directly owns all the outstanding capital stock of DuPont Pharma, Inc. E.I. du Pont de Nemours and Company directly owns all the outstanding capital stock of DuPont Chemical and Energy Operations, Inc. -----END PRIVACY-ENHANCED MESSAGE-----